Italian Biopharma company Gentium S.p.A. said its Defibrotide therapy shows a strong trend toward statistical significance in the prevention and treatment of Hepatic Veno-Occlusive Disease or VOD, a potentially life-threatening condition that typically occurs as an important complication of stem cell transplantation.
RTTNews